Potential lung cancer vaccine shows renewed promise

The investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer, a study has shown. "There aren't any good options for patients with inoperable stage III lung cancer following mainline chemotherapies," said the lead author. "We are looking at tecemotide as a potential maintenance therapy to prolong survival and improve quality of life."